Benign recurrent intrahepatic cholestasis (BRIC) is a hereditary liver disorder characterized by intermittent episodes of intrahepatic cholestasis, generally without progression to chronic liver damag...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 7, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 7, 2026
The documentation surrounding benign recurrent intrahepatic cholestasis is limited primarily due to its rarity and the lack of established genetic markers. Since BRIC affects a small population, comprehensive clinical studies have been scarce. Additionally, the overlap of symptoms with other cholestatic disorders complicates clear characterization. As research continues, there is hope that more insights will emerge, leading to better understanding and management of this condition.
The clinical features of benign recurrent intrahepatic cholestasis primarily affect the liver and include symptoms such as jaundice, which occurs in 80-99% of patients, and pruritus (itching), also affecting 80-99%. Other common symptoms include fatigue, anorexia, and acholic stools, all present in 80-99% of cases. Patients may also experience elevated hepatic transaminase levels and weight loss, with nausea and vomiting occurring in 30-79% of cases. Abdominal pain is less common, affecting 5-29% of individuals.
To navigate your condition effectively, consider consulting a hepatologist with expertise in cholestatic liver diseases. They can provide specialized care and help manage symptoms. Additionally, you may want to explore clinical trials for benign recurrent intrahepatic cholestasis, which can be found at ClinicalTrials.gov. While there are currently no identified patient organizations, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable information and support. Genetic counseling may also be beneficial to discuss family implications, even though a genetic basis is not yet established.
Currently, there are no orphan drug designations for benign recurrent intrahepatic cholestasis, but there is one active clinical trial that may provide insights into potential treatments or management strategies. You can find more information about this trial at ClinicalTrials.gov by searching for benign recurrent intrahepatic cholestasis. Participation in clinical trials can be an important avenue for accessing new therapies and contributing to research.
Actionable guidance for navigating care for benign recurrent intrahepatic cholestasis
To navigate your condition effectively, consider consulting a hepatologist with expertise in cholestatic liver diseases. They can provide specialized care and help manage symptoms. Additionally, you may want to explore clinical trials for benign recurrent intrahepatic cholestasis, which can be found at ClinicalTrials.gov. While there are currently no identified patient organizations, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable information and support. Genetic counseling may also be beneficial to discuss family implications, even though a genetic basis is not yet established.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 7, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.